2029-49-4

Basic information

• Product Name: 3-HYDROXY-2,6-BIS(HYDROXYMETHYL)-4-PYRONE
• Synonyms: 3-HYDROXY-2,6-BIS(HYDROXYMETHYL)-4-PYRONE
• CAS NO: 2029-49-4
• Molecular Formula: C₇H₈O₅
• Molecular Weight: 172.14
• Mol File: 2029-49-4.mol
• Article Data: 7

Chemical Properties

• Melting Point: 149 °C(dec.)
• Boiling Point: 496.5°C at 760 mmHg
• Flash Point: 213.7°C
• Appearance: /
• Density: 1.583g/cm³
• Vapor Pressure: 6.15E-12mmHg at 25°C
• Refractive Index: 1.617
• Solubility: Methanol
• CAS DataBase Reference: 3-HYDROXY-2,6-BIS(HYDROXYMETHYL)-4-PYRONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-HYDROXY-2,6-BIS(HYDROXYMETHYL)-4-PYRONE(2029-49-4)
• EPA Substance Registry System: 3-HYDROXY-2,6-BIS(HYDROXYMETHYL)-4-PYRONE(2029-49-4)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 2029-49-4(Hazardous Substances Data)

Usage

Uses

3-Hydroxy-2,6-bis(hydroxymethyl)-4-pyrone is a substance used in the experimental and computational crystal structure study of nigerloxin. nigerioxin is a fungal metabolite from Aspergillus niger.

InChI:InChI=1/C7H8O5/c8-2-4-1-5(10)7(11)6(3-9)12-4/h1,8-9,11H,2-3H2

Upstream product

• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 
• 50-00-0 formaldehyd 
• 64-17-5 ethanol 

Downstream Products

• 455922-89-1 3-(benzyloxy)-2,6-bis(hydroxymethyl)-4H-pyran-4-one 
• 958457-37-9 6-(hydroxymethyl)-2-methyl-3-(4-{[3(trifluoromethy)phenyl]oxy}phenyl)-pyridin-4(1H)-one 
• 958457-36-8 6-hydroxymethyl-2-methyl-3-(4-{4-[(trifluoromethyl)oxy]phenyl}oxy)-pyridinone 
• 958457-35-7 6-(hydroxymethyl)-2-methyl-3-(4-{[3(trifluoromethy)phenyl]oxy}phenyl)-4H-pyran-4-one 
• 958457-34-6 6-hydroxymethyl-2-methyl-3-(4-{4-[(trifluoromethyl)oxy]phenyl}oxy)-pyran-4(1H)-one 
• 1334392-90-3 C₂₄H₂₂ClF₃N₂O₄ 
• 1334392-87-8 C₂₄H₂₂ClF₃N₂O₃ 
• 1334392-85-6 C₂₂H₂₀ClF₃N₂O₃ 
• 958457-39-1 3-chloro-6-methyl-4-oxo-3-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-1,4-dihydro-2-pyridinecarbaldehyde 
• 69648-63-1 8-oxo-4,8-dihydro-6-(hydroxymethyl)-2-phenyl-4H-pyrano[3,2-d]-m-dioxin 
• 1506-67-8 3-hydroxy-6-hydroxymethyl-2-methyl-pyran-4-one 
• 497-59-6 meconic acid 

Relevant articles and documents

Poppy acid: Synthesis and crystal chemistry

It had long ago been reported that poppy acid crystals encapsulate and orient a great variety of molecules during solution growth and in so doing seem to egregiously violate the principle of isomorphism. To comprehend this surprising host-guest chemistry, and exploit it for measuring anisotropic molecular properties, we attempted to carry out the oft-used literature synthesis of poppy acid, (3-hydroxy-2,6-dicarboxyγ-pyrone), but discovered that the standard procedures did not produce the title compound. We instead obtained a constitutional isomer as the potassium salt of 2-oxaloate-3- hydroxy-5-carboxyfuran. Therefore, we designed and carried out the first total synthesis of poppy acid. It crystallizes as either of two polymorphs, an orthorhombic form (Pbca) and a monoclinic form (C2/c), both characterized by weakly bonded layers consistent with perfect cleavages. The great majority of the dyes tested, 15 of 19, produced poppy acid crystals colored in particular growth sectors displaying strong linear dichroism. The observation of pronounced absorption anisotropy is consistent with a general mixed crystal growth mechanism in which the dyes substitute for poppy acid molecules within the layers and are further oriented in the direction of hydrogen bound rows of molecules within layers.

A Convenient Preparation of Carboxy-γ-pyrone Derivatives: Meconic Acid and Comenic Acid

-

Potent antimalarial 4-pyridones with improved physico-chemical properties

Antimalarial 4-pyridones are a novel class of inhibitors of the plasmodial mitochondrial electron transport chain targeting Cytochrome bc1 (complex III). In general, the most potent 4-pyridones are lipophilic molecules with poor solubility in aqueous medi

Orally active iron (III) chelators

A compound of formula I wherein R is hydrogen or a group that is removed by metabolism in vivo to provide the free hydroxy compound, R1is an aliphatic hydrocarbon group or an aliphatic hydrocarbon group substituted by a hydroxy group or a carboxylic acid ester, sulpho acid ester or a C1-6alkoxy, C6-aryloxy or C7-10aralkoxy ether thereof, and R3is selected from hydrogen and C1-6alkyl; characterized in that R2is selected from groups (i) —CONH—R5(ii)—CR6R6OR7(iii) —CONHCOR5and (iv) —CON(CnH2n+1)2 R4is selected from hydrogen, C1-6alkyl and a group as described for R2; R5is selected from hydrogen and optionally hydroxy, alkoxy, aryloxy or aralkoxy substituted C1-13alkyl, aryl and C7-13alkyl R6is independently selected from hydrogen and C1-13alkyl, R7is selected from hydrogen, C1-13alkyl, aryl and C7-13aralkyl or a pharmaceutically acceptable salt of any such compound and CnH2n+1is C1-6alkyl with the proviso that the compound is not one of 1-ethyl-2-(1′-hydroxyethyl)-3-hydroxypyridin-4-one and 1-methyl-2-hydroxymethyl-3-hydroxypyridoin-4-one.